LOS ANGELES, September 26, 2017 /PRNewswire/ --
USA News Group - As mostinvestors already recognize, Canada has taken the early lead in the move towards legalization of marijuana. The calendar is set to lift prohibition in mid 2018 under the current government there.
First mover companies who are anticipating the change are moving at an ever increasing pace to stake their positions and grab market share in what may be the hay day for cannabis stocks.
Markets are embracing the trend and rewarding companies that show the ability to make real advances and grow revenue.
Early participants on the leading edge include Abattis Bioceuticals Corp. (OTCQB: ATTBF) (CSE: ATT.CN), which is set to make some major inroads with its licensed testing and timely extraction capabilities - one of the only public companies with this complete skill set.
On the production side, Canopy Growth Inc. (OTC: TWMJF) (TSX: WEED.TO) is one of the stars, soaring to as high as $13 per share in February of 2017, only to fall more than 40% to under $8 in May of this year.
Other companies in the growing cannabis space include AbbVie Inc. (NASDAQ: ABBV), and OrganiGram Holdings Inc. (OTCQB: OGRMF) (TSX-V: OGI.V) which are already a household name in this sector.
These players fall into the mega-producer category with massive facilities to grow and produce cannabis, with the exception of Abattis, who have smartly positioned themselves to become the go-to testing and research provider handling the needs of all cannabis producers.
Even at this relatively early stage, it is evident that the cannabis industry is experiencing nearly unprecedented growth. The value being generated as a result is exceptional - heading for CAGR projected as high as 25% through 2025.
Beyond the plant's basic use through straight consumption, medicinal or recreational, are several other derivatives that provide major potential for the industry as a whole.
North American marijuana sales grew by an unprecedented 30% in 2016 to $6.7 billion as the legal market expands in the U.S. and Canada, according to a new report by Arcview Market Research.
North American sales are projected to top $20.2 billion by 2021 assuming a compound annual growth rate of 25%. The report includes Canada for the first time as it moves towards implementing legal adult use marijuana.
The market for CBD alone hit $170 million in 2016, and is projected to grow $1 billion by 2020.
To reach these kind of massive numbers, the industry is going to need a lot of independent firms doing research and coming up with new and better extraction methods, formulations and enormous testing capacity.
HEDGING ON RESEARCH AND TESTING
The global cannabis testing market is expected to grow at a CAGR of 11.5%, culminating towards a $1.42 billion market by 2021.
This makes sense, since in order to deliver on big volumes, producers will need an accurate reading of the drug's potency, including the levels of the key medicinal components of cannabis, THC and CBD.
Producers all recognize that this will require a skilled and specialized third party to test their product before it goes to market.
This is the segment targeted directly by newcomer Abattis Bioceuticals.
The company has a full spectrum lab staffed with industry experts to ensure the quality standard required by producers and developers. Its subsidiary, Northern Vine Labs, will not be limited for testing, however. Another major component to the facility will be in extraction and formulation.
This means that the company will be involved in innovation of methods to extract medicinal components from cannabis on a massive industrial scale, and to formulate them for consumer products.
Research will become a critically important part of this industry as it grows.
ATT'S SWEET SPOT
All the growth and attention being paid to testing have put leading edge companies like ATT at the forefront. ATT for instance, is establishing multiple assets to become Canada's cannabis testing, formulation and extraction facility of choice.
Most of the companies in the cannabis space have entered through the producer's side of the business either cultivation or some aspect of production and distribution. Certainly the Canopy, Aurora, Aphria and others have focused on production.
This has created a large and potentially very profitable opening for those companies applying bioscience and technology on the leading edge of the cannabis business.
Even some of the mega stars have yet to tap into an even greater potential resource… one that's at the center of up and comer Abattis Bioceutical Corp.'s agenda.
Abattis Bioceuticals and its majority-owned subsidiary Northern Vine Labs have merged efforts to create a state-of-the-art testing and research company, supported by its fully licensed labs that provide for legal cannabis testing and formulations.
These combined operations will be one of the most sophisticated, Health Canada licensed operations in the country with the potential to handle virtually all forms of Cannabis testing and extraction development.
Through its unique position as one of only very few labs granted the licensing needed to test cannabis, ATT is securing its future in the cannabis sector. With the addition Northern Vine Labs for research and products through Vergence, the company is also opening its services to a very broad spectrum.
At this point it has the assets in place to vault its way up that of major status among the Auroras, Aphrias, and Canopys that are emerging. Those companies range from $800 million to $1.5 billion in market caps. Abattis Bioceuticals appears undervalued by comparison at a mere $24 million market cap.
ATT has diversified its operations into several segments, from research and certification in its testing and lab facilities, to formulations and extracts exclusive to Northern Vine Labs and to products provided by its Vergence subsidiary.
Although only recently established as a full spectrum R&D cannabis sector company, ATT has managed to bring together very valuable assets while tripling its price from a year ago. With the early interest and pent up demand for services, Abattis Bioceuticals looks like a serious leader as the cannabis sector seeks to build its infrastructure.
AbbVie Inc. (NASDAQ: ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C. Another product AbbVie markets is Marinol, which is a dronabinol capsule that is chemically identical to tetrahydrocannabinol, a.k.a. THC. AbbVie also has a long list of cannabinoid related patents. Some of these many patents include: Method for treating cannabinoid receptor related diseases with cannabinoid receptor ligands (U.S. Patent 12967275), Process for preparing cannabinoid receptor ligands (U.S. Patent 12969047), Combination therapy for reducing side effects using cannabinoid receptor ligands (European Patent 20080840052)
OrganiGram Holdings Inc. (OTCQB: OGRMF) (TSX-V: OGI.V)
OrganiGram Holdings Inc., through its subsidiary, Organigram Inc., produces and sells medical marijuana in Canada. Organigram is based in Moncton, New Brunswick. Though located at the heart of Atlantic Canada, They're committed to improving quality of life for their patients all across the country. For OrganiGram, this means working with healthcare providers and industry organizations, supporting research and education, and providing a safe, effective product.
Canopy Growth Inc. (OTC: TWMJF) (TSX: WEED.TO)
The granddaddy of the corporate cannabis sector, Canopy Growth is the world's largest diversified cannabis company. Canopy boasts a wide offering of distinct brands and curated cannabis varieties in dried, oil and capsule forms. Most widely recognized is Canopy's subsidiary Tweed which is the world's most recognized marijuana production brand, as well as an industry educator. Accompanying Tweed in Canopy's portfolio is medical-grade cannabis producers Bedrocan Canada. In total, Canopy Growth's numerous state-of-the-art production facilities total over half a million square feet of GMP-certified indoor and greenhouse production capacity.
For a more in-depth look into ATT you can view the in-depth report at USA News Group: http://usanewsgroup.com/2017/09/11/biotech-sector-poised-to-deliver-more-health-and-wealth-2-2-2/
Legal Disclaimer/Disclosure: This piece is an advertorial and has been paid for. This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. No information in this Report should be construed as individualized investment advice. A licensed financial advisor should be consulted prior to making any investment decision. We make no guarantee, representation or warranty and accept no responsibility or liability as to its accuracy or completeness. Expressions of opinion are those of USA News Group only and are subject to change without notice. USA News Group assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this Report and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission. Furthermore, we assume no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information, provided within this Report.
DISCLAIMER: USA News Group is Source of all content listed above. FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with USA News Group or any company mentioned herein. The commentary, views and opinions expressed in this release by USA News Group are solely those of USA News Group and are not shared by and do not reflect in any manner the views or opinions of FNM. FNM is not liable for any investment decisions by its readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release.
FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Media Contact e-mail: firstname.lastname@example.org U.S. Phone: +1(954)345-0611
SOURCE USA News Group
Subscribe to our Free Newsletters!
Hay fever is caused by allergy to pollen and is characterized by runny or blocked nose, sneezing, ...
Therapeutic drug monitoring is measuring drug concentrations at specific intervals in a patient's ...
Sweet's syndrome or acute febrile neutrophilic dermatosis is a skin disorder with no specific ...View All